Abstract
Patients with chronic lymphocytic leukemia carrying a single TP53 hit (chromosome 17p deletion or single TP53 mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple TP53 hits. Testing TP53 deletion/mutation combining FISH and deep next-generation sequencing should be performed for a correct patient evaluation.See related article by Brieghel et al., p. 4531.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical cancer research : an official journal of the American Association for Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
